FRCS, formerly Research Senior Registrar, Norfolk and Norwich Hospital. Now Senior Registrar in Urology, St Peter's Hospitals and The Institute of Urology, London.
Distigmine Bromide and Post-Prostatectomy Voiding
Version of Record online: 21 NOV 2008
British Journal of Urology
Volume 55, Issue 2, pages 229–232, April 1983
How to Cite
SHAH, P. J. R., ABRAMS, P. H., CHOA, R. G., ASHKEN, M. H., GACHES, C. G. C., GREEN, N. A. and WILES, A. (1983), Distigmine Bromide and Post-Prostatectomy Voiding. British Journal of Urology, 55: 229–232. doi: 10.1111/j.1464-410X.1983.tb06563.x
- Issue online: 21 NOV 2008
- Version of Record online: 21 NOV 2008
Summary— Distigmine bromide (Ubretid) is a long-acting anticholinesterase which is thought to improve detrusor function, restoring normal voiding patterns which may have been disturbed by autonomic overactivity, particularly after surgery.
Ninety-three patients entered a double-blind study of the effect of distigmine bromide versus placebo on voiding after prostatectomy. The results demonstrated that there was a trend towards improvement but no statistically significant increase in post-operative flow rates, in reduction in bladder volume, and in the incidence of re-catheterisation in the patients treated with distigmine bromide.